Ovid Therapeutics (OVID) AI Stock Analysis

• Market Cap: $35.29M
• Dividend Yield: N/A
• Average Volume (3M): 2.36M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.95
• Revenue Growth: 15.73%
• EPS Growth: 51.00%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 71,109,510
• 10 Day Avg. Volume: 1,157,285
• 30 Day Avg. Volume: 2,359,313
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.18
• Enterprise Value/Revenue: -11.69
• Enterprise Value/Gross Profit: -16.02
• Enterprise Value/Ebitda: 0.11
• 1Y Price Target: $2.83
• Price Target Upside: 454.90% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 54 Neutral
• Price Target: $0.50 ▼(-1.96% Downside)

Ovid Therapeutics' overall stock score is influenced significantly by financial performance challenges, including inconsistent revenue and ongoing losses, which weigh down the score. The technical analysis offers a more positive view with upward momentum and neutral RSI, contributing positively. Valuation remains a concern due to negative earnings. The absence of earnings call data and corporate events leaves these areas without impact on the score.

Positive Factors

Drug Efficacy

OV329 has key advantages over Vigabatrin, including data suggesting that OV329 works at doses 1000x lower than Vigabatrin.

Financial Stability

The financial position of Ovid Therapeutics is stable, with sufficient cash to fund operations into the second half of 2026.

Safety Profile

OV329 shows no evidence of ocular accumulation in the current Phase 1 study, which is promising regarding its safety profile.

Negative Factors

Drug Rights

Takeda discontinued development of Soticlestat in Dravet syndrome, and Ovid does not regain rights to the drug, impacting revenue projections.

Price Target Reduction

The 12-month price target has been reduced to $1.50 from $2.

Ovid Therapeutics Business Overview & Revenue Model

Company Description

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

How the Company Makes Money

Ovid Therapeutics makes money primarily through the development and commercialization of its pharmaceutical products aimed at rare neurological disorders. The company's revenue model includes income from the sale of approved drugs, licensing agreements, and collaborations with other pharmaceutical companies. Ovid may also receive milestone payments and royalties as part of partnerships with larger firms, where they co-develop or out-license their drug candidates. These strategic partnerships are significant as they provide additional funding and resources necessary for advancing their drug pipeline through clinical trials and towards market approval.

Ovid Therapeutics Financial Statement Overview

Summary

Ovid Therapeutics faces challenges with revenue consistency and profitability, showing significant fluctuations in income and ongoing losses. Despite low debt, declining equity and persistent cash flow deficits raise concerns about financial sustainability. Improvements in reducing net losses are positive, but overall financial health remains precarious.

Income Statement

Ovid Therapeutics has experienced significant revenue volatility, with a decline from $208M in 2021 to $566K in 2024, indicating unstable revenue generation. The gross profit margin is consistently low, and negative EBIT and net income margins indicate ongoing losses. Recent improvements in reducing losses are positive, but profitability remains a challenge.

Balance Sheet

The company's debt-to-equity ratio is low, reflecting modest leverage, which is a positive indicator of financial stability. However, the declining stockholders' equity and total assets over recent years raise concerns about the company's ability to sustain its operations long-term. The equity ratio suggests a fair proportion of equity financing, but high liabilities relative to assets pose risks.

Cash Flow

Operating cash flow remains negative, reflecting ongoing cash burn, although there has been a slight improvement in free cash flow in 2024. The company has relied on financing activities to support cash flow, which could indicate difficulties in generating sufficient cash from operations. Continued negative free cash flow is a concern for long-term sustainability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	566.00K	391.69K	1.50M	208.38M	12.62M
Gross Profit	566.00K	-1.21M	121.14K	208.38M	12.62M
EBITDA	-61.27M	-57.69M	-54.17M	124.40M	-81.12M
Net Income	-26.43M	-52.34M	-54.17M	122.83M	-81.04M
Balance Sheet
Total Assets	92.17M	144.03M	155.27M	194.54M	75.93M
Cash, Cash Equivalents and Short-Term Investments	53.08M	105.83M	129.00M	187.80M	72.03M
Total Debt	14.76M	16.00M	16.54M	0.00	0.00
Total Liabilities	23.94M	56.23M	22.99M	14.80M	32.29M
Stockholders Equity	68.23M	87.80M	132.27M	179.75M	43.63M
Cash Flow
Free Cash Flow	-56.03M	-45.92M	-56.65M	118.42M	-51.97M
Operating Cash Flow	-55.96M	-45.78M	-55.23M	118.61M	-51.58M
Investing Cash Flow	54.59M	-2.58M	-87.88M	-1.82M	34.65M
Financing Cash Flow	622.00K	30.54M	180.66K	904.08K	47.07M

Ovid Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.51
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OVID, the sentiment is Neutral. The current price of 0.51 is below the 20-day moving average (MA) of 0.52, above the 50-day MA of 0.40, and below the 200-day MA of 0.63, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 54.22 is Neutral, neither overbought nor oversold. The STOCH value of 15.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OVID.

Ovid Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IPA	63 Neutral	$83.54M	―	-102.69%	―	-3.20%	12.24%
OVID	54 Neutral	$35.29M	―	-36.31%	―	15.73%	51.00%
PULM	53 Neutral	$20.01M	―	-83.85%	―	6.96%	32.32%
Sector *	51 Neutral	$7.39B	0.40	-62.86%	2.37%	15.56%	-1.99%
CALC	39 Underperform	$41.92M	―	-134.15%	―	―	95.48%
TENX	36 Underperform	$25.60M	―	-39.78%	―	―	84.17%
CVM	27 Underperform	$62.35M	―	-238.64%	―	―	30.96%

Ovid Therapeutics Corporate Events

Ovid Therapeutics Approves Key Proposals at Annual Meeting

On July 9, 2025, Ovid Therapeutics held its annual stockholders meeting, where several key proposals were voted on. Stockholders elected directors for a three-year term, approved executive compensation, ratified KPMG LLP as the accounting firm, and authorized a potential reverse stock split, indicating strategic financial adjustments.

The most recent analyst rating on (OVID) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.

Ovid Therapeutics Sells Ganaxolone Royalties to Immedica

On June 23, 2025, Ovid Therapeutics entered into an agreement with Immedica Pharma AB to sell its future royalties related to ganaxolone, a medicine used for treating CDKL5 deficiency disorder, for $7.0 million. This transaction provides Ovid with non-dilutive funding to support its operations, while Immedica gains control over ganaxolone’s intellectual property rights, enhancing its focus on rare diseases.

The most recent analyst rating on (OVID) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.